For all neurosarcoidosis patients, a clinical trial in the Baltimore area entitled, “Clinical Biomarkers of Disease Activity and Treatment Response in Patients with CNS Sarcoidosis Treated with H.P. Acthar Gel”, is now open for recruitment specifically to patients in the Baltimore, MD area at the University of Maryland School of Medicine.
The purpose of this study is to determine whether the use of Acthar Gel can reduce chronic inflammation in neurosarcoidosis patients, ultimately improving quality of life. The testing of blood and spinal fluid will be the indication of Acthar’s effectiveness.
To qualify patients must:
- a) Diagnoses of sarcoidosis with involvement of the central nervous system.
- b) If on steroids, be on a stable dose of the medication for at least three months.
- c) At the time of enrollment have a history of clinical deterioration and worsening symptoms.
Patients will be required to be present on the site every 1 to 3 months during the course of the study.
For questions or enrollment interest, please contact:
Health Program Director